AbbVie's Billion-Dollar Problem

AbbVie (NYSE: ABBV  ) shareholders are happy, happy, happy. Shares are up more than 27% since the company's spin-off from Abbott Labs (NYSE: ABT  ) in January. With such great performance, it's easy to overlook the negatives. The fact is, though, that AbbVie has a problem on its hands. A billion-dollar problem.

That problem certainly isn't Humira. Sure, AbbVie's megablockbuster anti-inflammatory drug goes off patent in a few years, but it continues to experience solid sales growth. AbbVie's billion-dollar problem is looking it straight in the eyes right now.

Billion-dollar threat
Cholesterol drugs Tricor and Trilipix combined to generate sales of $1.1 billion in 2012. However, that was a big drop from the almost $1.4 billion made the prior year. In the second quarter of 2013, sales for Tricor/Trilipix dropped 50% year-over-year. What's the culprit behind the hemorrhaging revenue? Generic competition.

For years, Abbott Labs successfully fended off the emergence of generic versions of Tricor. Teva Pharmaceuticals (NYSE: TEVA  ) ultimately secured a settlement with Abbott in 2009 that allowed it to gain rights to market a generic form of Tricor in 2011. However, Teva didn't actually launch its generic until 2012 -- but it immediately began to eat into Abbott's sales.

AbbVie now faces more competition. Mylan Pharmaceuticals (NASDAQ: MYL  ) launched its generic version of Tricor in May 2013. This launch followed litigation between Abbott and Mylan that was eventually settled in the fourth quarter of 2012.

Unfortunately, AbbVie doesn't have another cholesterol drug to make up for the sinking revenue. The company's Niaspan is another big seller in the cholesterol market, bringing in $911 million last year. However, Niaspan also faces generic competition. 

Even without generic rivals for Niaspan, AbbVie has other difficulties with the drug. Clinical study results announced by Merck (NYSE: MRK  ) last December cast doubts as to whether niacin products such as Niaspan actually improve outcomes for patients. Merck ended up asking doctors not to prescribe Tredaptive, its extended-release version of niacin with laropiprant, to new patients.

Plugging the leaks
The light certainly appears to be fading for AbbVie's prospects in the cholesterol drug market. Tricor and Trilipix are already losing sales rapidly. Niaspan's revenue will undoubtedly begin to decline significantly in the near future. AbbVie doesn't have any cholesterol drugs in its mid-stage or late-stage pipeline.

That's by design. AbbVie's focus is now on specialty drugs that have relatively few current therapies available. The company is pinning its hopes on replacing lost revenue from Tricor, Trilipix, and Niaspan from strong contenders in its pipeline in other therapeutic areas.

One drug that could plug the revenue leaks is Parkinson's disease gel Levadopa/Carbidopa. The drug is already marketed in Europe under the brand name Duodopa. AbbVie expects potential U.S. approval in the first half of 2014. Some see worldwide peak sales hitting around $1 billion -- enough to go a long way in offsetting losses from Tricor.

AbbVie's biggest potential winner is its oral hepatitis C virus interferon-free combo. BMO Capital Markets projects that the drug could generate peak annual sales of around $1.7 billion even with other new products entering the market. AbbVie hopes to file for regulatory approval in the second quarter of 2014. If approved, the drug would be launched commercially in 2015.

Of course, the prospects of losing patent protection for Humira in a few years still hangs over AbbVie's head. But that's a $9 billion problem for another day.

You're very likely facing a problem, too -- although it's probably not a billion-dollar one. Tax increases that took effect at the beginning of 2013 affected nearly every American taxpayer. But with the right planning, you can face this problem head-on by taking steps to take control of your taxes and potentially even lower your tax bill. In our brand-new special report "How You Can Fight Back Against Higher Taxes," The Motley Fool's tax experts run through what to watch out for in doing your tax planning this year. With its concrete advice on how to cut taxes for decades to come, you won't want to miss out. Click here to get your copy today -- it's absolutely free.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2583489, ~/Articles/ArticleHandler.aspx, 9/1/2014 10:09:28 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement